Besario, Nurman A.

HRN: 26-64-17  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/06/2025
CO-AMOXICLAV 625MG (TAB)
02/06/2025
02/13/2025
PO
625 Mg/tab
Q12
Wound And Abrasions
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: